[headline announcement Nuggets]

Genscript Biotech Corporation (01548): the adjusted net profit of the acellular therapy business is expected to be about US $29 million to US $31.8 million in the first half of the year.

Genscript Biotech Corporation said in a notice that the adjusted net profit of the group business except the cell therapy business (Legend Biotech Corp) maintained a steady growth, with an expected growth of about 10.3% to 20.9%. The acellular therapy business (Prosperity) is expected to make an adjusted net profit of approximately $29 million to $31.8 million, compared with approximately $26.3 million for the same period in 2021. The increase is mainly due to the continued improvement in the profitability of the Group's CDMO and synthetic Biology businesses.

Cell therapy business: Legend Biotech Corp is expected to make an adjusted loss of about $196 million to $229 million, mainly from research and development spending of about $135 million to $158 million, mainly due to continued investment in its main candidate Cedar Orange and other potential candidates.

Comments:Genscript Biotech Corporation has become an international biotechnology company covering life science services, biomedical CDMO, cell therapy and industrial synthetic biological products. Between 2015 and 2021, revenue grew from $87 million to $511 million, with CAGR reaching 34.3%.

Booming Biology, a subsidiary of the company, is a biological drug CDMO enterprise with full process coverage. Its CDMO service covers two areas of antibody protein drugs and CGT, covering the whole process from drug discovery to clinical development. In order to meet the innovative needs in the research and development of antibody protein drugs, the double antibody platform and CAR candidate molecule discovery service are launched. In the aspect of GCT, it provides the overall plan for the production and clinical application of GMP, which are commonly used vectors such as plasmid, lentivirus and AAV.

Legend Biotech Corp is a leading international cell therapy company, which was listed on NASDAQ in 2020 and has the world's leading cell therapy products. Cedarkey Orange, the fastest-growing BCMA CART product, has shown potential best-in-class advantages in clinical trials, and has obtained conditional listing permission from FDA and EMA. It is the first domestic CAR-T to successfully go to sea, and is expected to contribute high milestone payments and sales revenue to the company.

At present, the company is seizing the opportunity to give full play to the synergy of the whole industry chain, taking the gene and cell therapy (GCT) industry chain and the synthetic biology industry chain as the focus of layout, and the investment is expected to bring a new growth curve.

[key announcement Nuggets]

The 3711.04GWh of equity generation in the first 7 months of Xiehe New Energy (00182), an increase of 21.57% over the same period last year.

According to the Xiehe New Energy announcement, in July 2022, the equity generation of wind power was 311.42GWH, that of solar power was 84.5GWh, an increase of 260.34% over the same period last year, and the total equity generation 395.92GWh, an increase of 1.34% over the same period last year.

In the first seven months, the equity generation of wind power was 3270.22GWh, up 12.34% from the same period last year; the equity generation of solar power was 440.82GWh, up 211.6% from the same period last year; and the total equity generation was 3711.04GWh, up 21.57% from the same period last year.

Comments:Xiehe New Energy focuses on wind and photovoltaic power generation services. The company has made great efforts to develop renewable energy power generation business, and is expected to add 9-1000 megawatts of equity installed capacity each year in 2022-2024. The company's newly built wind power project can achieve an annual rate of return of 15-20%.

In recent years, through asset replacement to optimize asset quality, reduce power generation costs, sell power plants with relatively low utilization hours, implement fan efficiency technical transformation, the company's power plant operation quality has been greatly improved. The weighted average hours of wind power utilization in 2021 is 2411 hours, an increase of 170hours over last year and 165hours higher than the national average. In addition, as the company's parity projects continue to participate in green card transactions, the revenue level of the company's parity projects will be improved in the future.

The company's operation and maintenance business has great potential. As the largest third-party operation and maintenance company in China, the operation and maintenance capacity has exceeded 11 gigawatts, and the operation and maintenance income exceeds 10% of the company's total income, and has rich practical experience. In recent years, Xiehe operation and maintenance has reshaped wind power operation and maintenance management through comprehensive digital transformation, created competitive operation and maintenance service products, and ensured the sustainable growth of the enterprise.

Us East Motor (01268): a final dividend of HK81.34 cents per share in 2021

East American Motor announced that it declared a final dividend of 0.6991 yuan per common share, or HK $0.8134 per share, for the year ended December 31, 2021.

Comments:Meidong Automobile is a typical example of small and beautiful dealers, with far less stores, revenue and profitability than other dealers, but far more profitable than other dealers. Mainly acting BMW, Lexus and other 6 brands.

Fine management capabilities, including continuously improved inventory turnover speed; a substantial increase in after-sales service absorption rate, indicating a substantial increase in after-sales service profits; strong cost control ability, sales management expense rate gradually decreased with scale expansion; financial expense rate is also lower than that of other dealers.

Differentiated marketing strategies include adhering to a few highly profitable and efficient luxury cars and Japanese brands, with store CR3 as high as 85%, luxury cars and Japanese cars contributing 81.3% and 38.3% of revenue, respectively, and adhering to the strategy of "single city and single store in low-line cities", giving the company a monopoly advantage in specific areas.

The company announced in December 2021 that it intends to acquire a 100% stake in the company, involving seven Porsche stores in seven cities, namely, Nanjing, Qingdao, Tianjin, Chongqing, Weifang, Jinan and Zhengzhou. And Qiuxing Motor has other authorized brands except Porsche, which is not included in the scope of acquisition and will be spun off from Qiuxing Automobile through restructuring. The merger and acquisition was completed in May this year. Meidong has 14 Porsche authorized 4S stores and a total of 23 outlets, making it one of the largest Porsche distribution groups in China.

[list of important announcements for Hong Kong stocks]